COVID-19 patients with blood cancers benefit from convalescent plasma, study shows
SAN ANTONIO - Latest data analysis is showing convalescent plasma can improve the survival rate of coronavirus patients with blood cancers.
Data from the Cancer Consortium showed a 48% reduced risk of death and 60% reduced risk for COVID-19 patients who were admitted to an intensive care unit.
According to UT Health San Antonio doctors, the findings can make a difference in care for blood cancer patients.
“We looked at the retrospective study and we examined if they had received convalescent plasma – was there a difference in their survival compared to someone who had no received it,” said Dr. Dimpy Shah with University of Texas Health Science Center at San Antonio.
The study looked at data from 143 patients who were given the convalescent plasma and 823 who did not.
Convalescent plasma is from people who have survived COVID-19.
“We hope to have a clinical trial which can show the benefit – the survival benefit in these patients – that would be an option if they ever get COVID,” added Dr. Shah.
To learn more about the findings, click HERE.
